Adalvo, in collaboration with its regional partner, has successfully launched Solifenacin/Tamsulosin in various LATAM markets, marking the first generic entry of this therapy in the region.
More launches across the region are set to follow, highlighting Adalvo’s commitment to expanding access to high-value treatments.
Based on the bioequivalent version of Vesomni MR Tablets (6mg/0.4mg), Solifenacin/Tamsulosin is indicated for the treatment of moderate to severe storage and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men.
With total global sales reaching $109 million in 2024 (IQVIA), Solifenacin/Tamsulosin continues to show strong market potential.
Adalvo’s clear IP strategy and regulatory expertise have enabled a first-to-market position, strengthening its presence in the urology segment.
Contact our team to explore commercial opportunities.